Take off the reading glasses once a day!

On November 30, 2021, Visus Therapeutics announced that a phase 2 clinical trial evaluating the efficacy of the innovative eye drops Brimochol under development has achieved positive results

Presbyopia is a common vision loss that occurs with age, affecting billions of people worldwide

Visus' research product, Brimochol, is an eye drop designed to be administered once a day to correct near vision loss associated with presbyopia

A total of 85 patients with presbyopia between the ages of 45-80 were enrolled in this dose-exploring, multi-center, three-arm phase 3 clinical trial

The results of the test showed that in the three treatment groups, at least 83% of the subjects had an increase in DCNVA, which is an index for detecting near vision, by at least 3 lines within 1 hour of treatment, and a decrease in distance vision index by less than 1 line

Reference materials:

[1] Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopia.